REUN Supplier Profile: What Reunion Neuroscience’s PR and Distribution Relationships Reveal to Investors

Reunion Neuroscience is a clinical-stage biopharmaceutical company focused on Luvesilocin (RE104) for postpartum depression and related indications. The company currently monetizes through equity financing and milestone-driven value creation tied to clinical results and regulatory events; market value appreciation will depend on successful late-stage development, regulatory approvals, and downstream commercialization or licensing. Investor focus should be on clinical and regulatory catalysts—communications and distribution suppliers play an outsized role in shaping market reception of those catalysts. For a concise supplier-risk scan and ongoing monitoring tools, visit the Zero Exposure homepage: https://nullexposure.com/.

Operational profile and business model drivers

• Reunion operates as a capital-intensive, early-stage developer where value is realized through discrete clinical and regulatory milestones rather than recurring product revenue. That model makes investor communications, financing rounds, and third-party distribution channels critical to capital access and valuation.
• Supplier posture is transactional and PR-focused: Reunion relies on third-party public relations and newswire services to distribute clinical updates, investor conference notices, and financing announcements. These suppliers influence investor perception and timing of capital markets responses.
• Concentration risk is material at the company level: multiple press releases list the same PR/IR contacts, indicating a concentrated communications arrangement that amplifies single-vendor operational risk if service continuity degrades.
• Maturity profile is early-stage: the company demonstrated a Series A close in 2025 and is generating clinical and regulatory milestones through 2026. Supplier relationships reflect startup-era needs—outsourced investor relations and news distribution instead of in-house channels.

If you evaluate supplier exposure for portfolio companies, this profile is informative—explore more supplier intelligence at https://nullexposure.com/.

What the public record shows — each relationship tested in the results Below I cover every relationship entry surfaced in the results set. Each item is summarized in plain English with a source reference.

1. Manila Times (GlobeNewswire syndicated) — investor conference notice, Feb 19, 2026
   Reunion announced participation in upcoming investor conferences and listed PR/IR contacts routed through Precision AQ (Hannah Deresiewicz for IR; Ashley Murphy for PR). This confirms a consistent IR/PR contact structure under Precision AQ for investor communications. Source: ManilaTimes run of a GlobeNewswire release (Feb 19, 2026). https://www.manilatimes.net/2026/02/19/tmt-newswire/globenewswire/reunion-neuroscience-to-participate-in-upcoming-investor-conferences/2281069/amp

2. Yahoo Finance — Series A closing copy with Precision AQ contact, FY2025
   A Yahoo Finance page republished a release announcing Reunion’s final closing of its Series A financing, and included Precision AQ contact details for IR and PR, signaling that Precision AQ handled investor-facing release distribution during the financing. Source: Yahoo Finance (Sept 16, 2025 run). https://finance.yahoo.com/news/reunion-neuroscience-announces-final-closing-113000685.html

3. Yahoo Finance (Singapore) — investor conference announcement, FY2026
   The Singapore variant of Yahoo Finance syndicated a release indicating conference participation and listed Precision AQ as the IR/PR point of contact, reinforcing the use of syndicated financial news outlets for broad reach. Source: Yahoo Finance SG (Feb 2026). https://sg.finance.yahoo.com/news/reunion-neuroscience-participate-upcoming-investor-123000816.html

4. GlobeNewswire — positive topline RECONNECT Phase 2 results, Aug 18, 2025
   Reunion released positive topline results from the RECONNECT Phase 2 trial for RE104 in postpartum depression; the release included Precision AQ contacts for IR/PR (notably Genevieve Britton listed for PR in this instance). This is a substantive clinical milestone that drives the company’s valuation trajectory. Source: GlobeNewswire (Aug 18, 2025). https://www.globenewswire.com/news-release/2025/08/18/3134924/0/en/Reunion-Neuroscience-Announces-Positive-Topline-Results-from-RECONNECT-Phase-2-Clinical-Trial-of-RE104-for-the-Treatment-of-Postpartum-Depression-PPD.html

5. GlobeNewswire — investor conference participation, Feb 19, 2026
   A direct GlobeNewswire release announcing investor conference participation again listed Precision AQ as the IR/PR handler, confirming the company’s preference for a dedicated external communications firm and for newswire distribution to reach investor audiences. Source: GlobeNewswire (Feb 19, 2026). https://www.globenewswire.com/news-release/2026/02/19/3240980/0/en/reunion-neuroscience-to-participate-in-upcoming-investor-conferences.html

6. GlobeNewswire — FDA Breakthrough Therapy Designation for RE104, Feb 23, 2026
   Reunion announced that the U.S. FDA granted Breakthrough Therapy Designation for Luvesilocin (RE104), with PR/IR contacts listed through Precision AQ. This regulatory milestone materially enhances the asset’s development value and de-risks regulatory timelines. Source: GlobeNewswire (Feb 23, 2026). https://www.globenewswire.com/news-release/2026/02/23/3242518/0/en/U-S-FDA-Grants-Reunion-Neuroscience-s-Luvesilocin-RE104-Breakthrough-Therapy-Designation-Status.html

7. GlobeNewswire — full RECONNECT Phase 2 data presented at ACNP, Jan 20, 2026
   Reunion presented full RECONNECT Phase 2 data at the ACNP Annual Meeting and distributed a GlobeNewswire release with Precision AQ contacts, indicating coordinated scientific communications timed to an academic forum and investor outreach. Source: GlobeNewswire (Jan 20, 2026). https://www.globenewswire.com/news-release/2026/01/20/3221591/0/en/Reunion-Neuroscience-Presents-Full-Data-from-RECONNECT-Phase-2-Clinical-Trial-of-RE104-for-the-Treatment-of-Postpartum-Depression-PPD-at-ACNP-Annual-Meeting.html

8. Yahoo Finance — REKINDLE presentation report, FY2025
   Yahoo Finance carried a release noting Reunion’s presentation of REKINDLE phase data (presentation context and PR/IR contact details listed), supporting a pattern of distributing scientific updates via financial news outlets to reach investors and analysts. Source: Yahoo Finance (FY2025). https://finance.yahoo.com/news/reunion-neuroscience-presents-rekindle-phase-113000998.html

9. Yahoo Finance — duplicate Series A closing syndication, FY2025
   A second Yahoo Finance entry republished the Series A closing announcement (MORRISTOWN, N.J., Sept. 16, 2025), confirming the Series A financing event and the use of syndicated outlets to amplify fundraising milestones. Source: Yahoo Finance (Sept 16, 2025). https://finance.yahoo.com/news/reunion-neuroscience-announces-final-closing-113000685.html

10. GlobeNewswire — Series A closing direct release, FY2025
    GlobeNewswire’s direct release announced the closing of Reunion’s Series A financing and described the company’s focus on psychedelic-inspired therapeutic solutions, confirming capital formation and positioning in mental health therapeutics. Source: GlobeNewswire (Sept 16, 2025). https://www.globenewswire.com/news-release/2025/09/16/3134924/0/en/Reunion-Neuroscience-Announces-Final-Closing-of-Series-A-Financing.html

Supplier implications and investment considerations

• Precision AQ functions as Reunion’s de facto communications supplier across IR and PR touchpoints; that concentration gives the vendor outsized influence on message timing and quality. Investors should treat the PR arrangement as a component of execution risk and monitor continuity of those relationships ahead of major milestones.
• GlobeNewswire and financial-syndication partners (Yahoo variants) are distribution suppliers that amplify clinical and financing events to investor audiences quickly. Those channels standardize reach but compress market reaction windows—expect swift pricing moves on releases hosted through these wires.
• Operational maturity signal: Series A close in 2025 plus consecutive clinical and regulatory milestones through 2026 indicates a classical early-growth trajectory where third-party communications and news distribution matter for capital raising and valuation realization.

Final read: risk versus runway Reunion’s supplier footprint is narrowly focused on PR/IR and newswire distribution—a logical posture for a clinical-stage company whose short-term value is message-driven. Supplier concentration on a single PR firm is a manageable operational choice so long as vendor performance, release timing, and regulatory disclosure align with investor expectations. From an investment standpoint, monitor the continuity of those supplier relationships and the cadence of milestone releases; they define the company’s public narrative and capital access over the next 12–24 months.

For ongoing supplier exposure research and alerts tied to Reunion and comparable issuers, go to https://nullexposure.com/. For a tailored supplier risk briefing for your portfolio, request a report at https://nullexposure.com/.